EU/3/20/2301

About

On 27 July 2020, orphan designation EU/3/20/2301 was granted by the European Commission to Bayer AG, Germany, for pegylated adrenomedullin (also known as PEG-ADM or BAY 1097761) for the treatment of acute respiratory distress syndrome.

Key facts

Active substance
Pegylated adrenomedullin
Disease / condition
Treatment of acute respiratory distress syndrome (ARDS)
Date of first decision
27/07/2020
Outcome
Positive
EU designation number
EU/3/20/2301

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Bayer AG
Kaiser-Wilhelm-Allee 1
Wiesdorf
51373 Leverkusen
Tel. +49 30 300139003
E-mail: clinical-trials-contact@bayer.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating